Last reviewed · How we verify
Dolutegravir / Lamivudine Pill
Dolutegravir inhibits HIV integrase to prevent viral DNA integration into the host genome, while lamivudine inhibits reverse transcriptase to block HIV replication.
Dolutegravir inhibits HIV integrase to prevent viral DNA integration into the host genome, while lamivudine inhibits reverse transcriptase to block HIV replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in adolescents and children (weight-based dosing).
At a glance
| Generic name | Dolutegravir / Lamivudine Pill |
|---|---|
| Also known as | Dovato |
| Sponsor | Charlotte-Paige Rolle, MD |
| Drug class | Antiretroviral combination (INSTI + NRTI) |
| Target | HIV integrase; HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
This combination tablet contains two antiretroviral agents with complementary mechanisms. Dolutegravir is an integrase strand transfer inhibitor (INSTI) that blocks the enzyme responsible for inserting viral DNA into human chromosomes. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that terminates the viral reverse transcription process. Together, they provide dual suppression of HIV replication at different stages of the viral lifecycle.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
- HIV-1 infection in adolescents and children (weight-based dosing)
Common side effects
- Insomnia
- Headache
- Diarrhea
- Nausea
- Fatigue
- Rash
Key clinical trials
- Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH) (PHASE4)
- B/F/TAF to DTG/3TC Switch Study (PHASE3)
- Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3 (PHASE4)
- DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV: (PHASE4)
- Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Successfully (PHASE2)
- Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING Study
- Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF (PHASE4)
- Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotyping Test (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dolutegravir / Lamivudine Pill CI brief — competitive landscape report
- Dolutegravir / Lamivudine Pill updates RSS · CI watch RSS
- Charlotte-Paige Rolle, MD portfolio CI